JP2002520282A - 慢性リンパ性白血病の処置のための方法および組成物 - Google Patents

慢性リンパ性白血病の処置のための方法および組成物

Info

Publication number
JP2002520282A
JP2002520282A JP2000558815A JP2000558815A JP2002520282A JP 2002520282 A JP2002520282 A JP 2002520282A JP 2000558815 A JP2000558815 A JP 2000558815A JP 2000558815 A JP2000558815 A JP 2000558815A JP 2002520282 A JP2002520282 A JP 2002520282A
Authority
JP
Japan
Prior art keywords
patient
group
hydrogen
indole
etodolac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000558815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002520282A5 (enExample
Inventor
フランシス エイ． ナーデラ，
ルース エル． シッザー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2002520282A publication Critical patent/JP2002520282A/ja
Publication of JP2002520282A5 publication Critical patent/JP2002520282A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2000558815A 1998-07-09 1999-07-08 慢性リンパ性白血病の処置のための方法および組成物 Pending JP2002520282A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9246698P 1998-07-09 1998-07-09
US60/092,466 1998-07-09
US9487898P 1998-07-29 1998-07-29
US60/094,878 1998-07-29
PCT/US1999/015501 WO2000002555A1 (en) 1998-07-09 1999-07-08 Methods and compositions for the treatment of chronic lymphocytic leukemia

Publications (2)

Publication Number Publication Date
JP2002520282A true JP2002520282A (ja) 2002-07-09
JP2002520282A5 JP2002520282A5 (enExample) 2006-10-05

Family

ID=26785713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000558815A Pending JP2002520282A (ja) 1998-07-09 1999-07-08 慢性リンパ性白血病の処置のための方法および組成物

Country Status (12)

Country Link
US (3) US6573292B1 (enExample)
EP (1) EP1104297B8 (enExample)
JP (1) JP2002520282A (enExample)
AT (1) ATE315392T1 (enExample)
AU (1) AU767586B2 (enExample)
CA (1) CA2336932A1 (enExample)
DE (1) DE69929440T2 (enExample)
DK (1) DK1104297T3 (enExample)
ES (1) ES2255287T3 (enExample)
NZ (1) NZ509376A (enExample)
PT (1) PT1104297E (enExample)
WO (1) WO2000002555A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69929440T2 (de) * 1998-07-09 2006-08-17 Cephalon, Inc. Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
US7105560B1 (en) * 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7361680B2 (en) 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7129262B2 (en) 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
WO2004026116A2 (en) 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
CA2540343A1 (en) * 2003-10-02 2005-04-14 Cephalon, Inc. Indole derivatives
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
MX2007005361A (es) * 2004-11-05 2008-01-11 Cephalon Inc Tratamientos para cancer.
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
GEP20156300B (en) * 2008-05-20 2015-06-25 Incuron Llc Inducing cell death by inhibiting adaptive heat shock response
WO2010036702A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
AU2010204765A1 (en) * 2009-01-15 2011-07-28 Cephalon, Inc. Novel forms of bendamustine free base
EP2605650A4 (en) 2010-08-18 2014-05-21 Del Mar Pharmaceuticals COMPOSITIONS AND METHODS FOR INCREASING THE THERAPEUTIC UTILITY OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYL DIANHYDROGALACTITOL
CA2863679A1 (en) 2011-08-17 2014-05-30 Dennis Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
CN110711188A (zh) 2012-01-20 2020-01-21 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US9814693B2 (en) 2012-05-09 2017-11-14 Delmar Pharmaceuticals, Inc. Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US10434086B2 (en) 2014-04-06 2019-10-08 Incuron, Inc. Combination therapies with curaxins
CA3023049A1 (en) 2016-05-04 2017-11-09 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
WO2019056123A1 (en) 2017-09-22 2019-03-28 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028148A2 (en) * 1995-03-13 1996-09-19 Loma Linda University Medical Center Use of a r-nsaid in a protective composition for the treatment of colorectal cancer
WO1997003667A1 (en) * 1995-07-19 1997-02-06 Merck & Co., Inc. Method of treating colonic adenomas
WO1998004527A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Pyranoindole and carbazole inhibitors of cox-2
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1071897B (enExample) 1957-12-19 1959-12-24
US3843480A (en) 1963-08-28 1974-10-22 D Dreher Dry dry transfer
US3948262A (en) 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3843681A (en) 1971-06-01 1974-10-22 American Home Prod 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives
US3939178A (en) 1971-06-01 1976-02-17 American Home Products Corporation Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles
US3974179A (en) 1971-06-01 1976-08-10 American Home Products Corporation 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetamides and derivatives
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3839178A (en) * 1972-10-05 1974-10-01 Gen Electric Potentiometric oxygen sensor
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
JPS5777617A (en) 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
IL61721A (en) 1980-12-16 1984-03-30 Blank Izhak Nitroglycerin preparations
US4542013A (en) 1981-07-08 1985-09-17 Key Pharmaceuticals, Inc. Trinitroglycerol sustained release vehicles and preparation therefrom
US4460562A (en) 1982-01-06 1984-07-17 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
US4542012A (en) 1982-07-02 1985-09-17 Minnesota Mining And Manufacturing Company Film-forming composition containing an antimicrobial agent and methods
US4608249A (en) 1982-11-02 1986-08-26 Nitto Electric Industrial Co., Ltd. Hydrophilic therapeutic material
IT1153909B (it) 1982-12-17 1987-01-21 Sogimi Srl Polimeri reattivi per la cura di affezioni cutanee
GB8317576D0 (en) 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4585877A (en) 1985-05-06 1986-04-29 American Home Products Corporation Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4748252A (en) 1986-08-15 1988-05-31 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids
US4686213A (en) 1986-08-15 1987-08-11 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
WO1993017680A1 (en) 1992-03-13 1993-09-16 Sepracor, Inc. Antipyretic and analgesic methods and compositions containing optically pure r-etodolac
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6160018A (en) 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5599946A (en) 1995-05-30 1997-02-04 Teva Pharmaceutical Industries Ltd. 3-(2-trialkylsilyloxy)ethyl-7-ethyl-1H-indoles and method for their preparation
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
AU3641597A (en) 1996-06-21 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions comprising r-ibuprofen
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
DE69929440T2 (de) * 1998-07-09 2006-08-17 Cephalon, Inc. Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
WO2002012188A2 (en) 2000-08-09 2002-02-14 The Regents Of The University Of California Indole compounds useful for the treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028148A2 (en) * 1995-03-13 1996-09-19 Loma Linda University Medical Center Use of a r-nsaid in a protective composition for the treatment of colorectal cancer
WO1997003667A1 (en) * 1995-07-19 1997-02-06 Merck & Co., Inc. Method of treating colonic adenomas
WO1998004527A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Pyranoindole and carbazole inhibitors of cox-2
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis

Also Published As

Publication number Publication date
PT1104297E (pt) 2006-05-31
AU767586B2 (en) 2003-11-20
AU5209899A (en) 2000-02-01
EP1104297A4 (en) 2003-01-02
DK1104297T3 (da) 2006-05-29
EP1104297A1 (en) 2001-06-06
NZ509376A (en) 2003-10-31
ATE315392T1 (de) 2006-02-15
US6573292B1 (en) 2003-06-03
US20050261356A1 (en) 2005-11-24
WO2000002555A1 (en) 2000-01-20
US20030232874A1 (en) 2003-12-18
ES2255287T3 (es) 2006-06-16
US6921772B2 (en) 2005-07-26
CA2336932A1 (en) 2000-01-20
DE69929440T2 (de) 2006-08-17
EP1104297B8 (en) 2006-05-03
DE69929440D1 (de) 2006-04-06
EP1104297B1 (en) 2006-01-11

Similar Documents

Publication Publication Date Title
JP2002520282A (ja) 慢性リンパ性白血病の処置のための方法および組成物
DE69801680T2 (de) Zusammensetzungen welche aldosereductasehemmer und glycogen phosphorylase hemmer enthalten
CN108289960B (zh) Ep4受体拮抗剂用于治疗nash相关肝癌的用途
JPH10513463A (ja) うっ血性心不全の治療へのカルバゾール化合物の利用
JP2002523447A (ja) ５−ｈｔ６アンタゴニストの使用
JP7223998B2 (ja) Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
TW201919612A (zh) 包含帕博西尼（ｐａｌｂｏｃｉｃｌｉｂ）及６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧基苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－甲酸的組合
CN104023715A (zh) 激酶抑制剂的副作用降低剂
JP2003529542A (ja) 癌の治療のためのエトドラクの使用
TW200416031A (en) Therapeutic treatment
JP2025087716A (ja) 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
EP1123702A1 (en) Analgesics
JP2022500485A (ja) グラピプラント単位剤形
KR20040106422A (ko) 간암 및 다른 암 질병 치료용 에포틸론 유도체
HUP9904243A2 (hu) Eljárás a Fas expressziójának gátlására
KR100377280B1 (ko) 디아릴알킬피페리딘을함유하는다중-약물내성종양치료효력증강용약제학적조성물
EP1671631A2 (en) Compositions for the treatment of chronic lymphocytic leukemia
JP2003238414A (ja) 医薬組成物
Wechter et al. Pillsbury Winthrop LLP
HUP0401696A2 (hu) Angiotenzin-II receptor antagonistát tartalmazó gyógyászati készítmény
CN121177494A (zh) Ipi549和bmn673联合在治疗白血病中的应用
MXPA04003136A (es) Formulaciones farmaceuticas solidas en solucion suspension y emulsion conteniendo paracetamol acido ascorbico y loratadina.
WO2007020509A1 (en) Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
JP2004002353A (ja) 医薬組成物
JP2000191533A (ja) 鎮痛剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100423